Biotech Values

[DewDiligence]

I heard the webcast you’re referring to and, notwithstanding what the doctor from MGH said, I think the distinction is mostly semantic. Insofar as metastatic prostate cancer is terminal and a large proportion of the deaths come from skeletal events and their complications (such as VTE), the boundary between treating the cancer and treating/preventing the bone mets is not well defined, IMO.